Monte Rosa Therapeutics said new preclinical AACR data support its selective CCNE1-targeting molecular glue degrader as a potential precision oncology approach

Monte Rosa Therapeutics said new preclinical AACR data support its selective CCNE1-targeting molecular glue degrader as a potential precision oncology approach for CCNE1-altered cancers. The update also points to broader pipeline progress, including MRT-6160.